News Release

GNI Group Receives Manufacture Approval for F647 from China FDA for First Idiopathic Pulmonary Fibrosis Drug in China

• Notice for F647 commercial name
• （Amendment）GNI Group Receives Manufacture Approval for F647 from China FDA for First Idiopathic Pulmonary Fibrosis Drug in China